Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Energenesis Biomedical CO.,LTD. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$52.20 |
52 Week High | NT$72.10 |
52 Week Low | NT$45.90 |
Beta | 0.57 |
11 Month Change | -6.28% |
3 Month Change | -3.33% |
1 Year Change | -21.86% |
33 Year Change | 3.57% |
5 Year Change | 0% |
Change since IPO | 68.39% |
Recent News & Updates
Shareholder Returns
6657 | TW Biotechs | TW Market | |
---|---|---|---|
7D | 3.8% | 10.2% | 6.5% |
1Y | -21.9% | 16.9% | 31.4% |
Return vs Industry: 6657 underperformed the TW Biotechs industry which returned 16.9% over the past year.
Return vs Market: 6657 underperformed the TW Market which returned 31.4% over the past year.
Price Volatility
6657 volatility | |
---|---|
6657 Average Weekly Movement | 4.9% |
Biotechs Industry Average Movement | 6.2% |
Market Average Movement | 5.7% |
10% most volatile stocks in TW Market | 9.4% |
10% least volatile stocks in TW Market | 2.9% |
Stable Share Price: 6657 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6657's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 35 | Han-min Chen | www.energenesis-biomedical.com |
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control.
Energenesis Biomedical CO.,LTD. Fundamentals Summary
6657 fundamental statistics | |
---|---|
Market cap | NT$3.98b |
Earnings (TTM) | -NT$199.00m |
Revenue (TTM) | NT$6.78m |
587.0x
P/S Ratio-20.0x
P/E RatioIs 6657 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6657 income statement (TTM) | |
---|---|
Revenue | NT$6.78m |
Cost of Revenue | NT$1.77m |
Gross Profit | NT$5.01m |
Other Expenses | NT$204.01m |
Earnings | -NT$199.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.61 |
Gross Margin | 73.90% |
Net Profit Margin | -2,936.00% |
Debt/Equity Ratio | 0% |
How did 6657 perform over the long term?
See historical performance and comparison